

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/591,224
IA Filing Date	March 4, 2005
First Named Inventor	James RUSSELL
Group Art Unit	1634
Examiner Name	Katherine SALMON
Attorney Docket Number	RUSSELL-4

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>9</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	A					

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/KS/	1	Ogus, A.C. et al. "The Arg753G1n Polymorphism of the Human Toll-like Receptor 2 Gene in Tuberculosis Disease." <i>Eur. Resp. J.</i> , 2004, vol. 23, no. 2: 219-223	
/KS/	2	Bochud, P.-Y. et al. "Cutting Edge: A Toll-like Receptor 2 Polymorphism That is Associated with Lepromatous Leprosy is Unable to Mediate Mycobacterial Signaling." <i>J. Immunol.</i> , The Williams and Wilkins Co., Baltimore, U.S. 2003, 170: 3451-3454	

Examiner Signature	/Katherine Salmon/	Date Considered	03/03/2011
-----------------------	--------------------	--------------------	------------

**CERTIFICATION STATEMENT**

- [ ] That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).
- OR
- [ ] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).
- [ ] See attached certification statement.
- [ ] Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- [XX] None

**SIGNATURE**

Signature /Shmuel Livnat/ Date (YYYY-MM-DD) 2010-04-29

Name/Print Shmuel Livnat Registration Number: 33,949

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.